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Abstract.  Thrombospondin (TS) is an extracellular 
glycoprotein whose synthesis and secretion by vascular 
smooth muscle cells (SMC) is regulated by platelet- 
derived growth factor. We have used a panel of five 
monoclonal antibodies against TS to determine an es- 
sential role for thrombospondin in the proliferation of 
cultured rat aortic SMC. All five monoclonal antibod- 
ies inhibited SMC growth in 3-d and extended cell 
number assays; the growth inhibition was specific for 
anti-TS IgG. The effects of one antibody (134.6) were 
examined in detail and were found to be reversable 
and dose dependent. Cells treated with D4.6 at 50 
Ixg/ml (which resulted in a >60%  reduction in cell 
number at day 8) were morphologically identical to 
control cells. D4.6-treated SMC were analyzed by flow 
cytofluorimetry and were found to be arrested in the 
G1 phase of the cell cycle. To determine a possible 
cellular site of action of TS in cell growth, SMC were 
examined by immunofluorescence using a polyclonal 
antibody against TS. TS was observed diffusely bound 
to the cell surface of serum- or platelet-derived growth 
factor-treated cells. The binding of TS to SMC was 
abolished in the presence of heparin, which prevents 
the binding of TS to cell surfaces and inhibits the 
growth of SMC.  Monoclonal antibody D4.6,  like hepa- 
tin, largely abolished cell surface staining of TS but 
had no detectable effect on the cellular distribution of 
fibronectin. These results were corroborated by meta- 
bolic labeling experiments. We conclude that cell sur- 
face-associated TS is functionally essential for the 
proliferation of vascular SMC, and that this require- 
ment is temporally located in the G~ phase of the cell 
cycle. Agents that perturb the interaction of TS with 
the SMC surface, such as heparin, may inhibit SMC 
proliferation in this manner. 
T  HROMBOSPONDIN (TS) ! is a platelet- and cell-derived 
homotrimeric glycoprotein of Mr 450,000 (see Silver- 
stein et al., 1986; Lawler 1986; Majack and Bornstein, 
1987 for recent reviews). The complete amino acid sequence 
of  thrombospondin has recently been deduced  from sequenc- 
ing cDNAs from endothelial (Lawler and Hynes, 1986) and 
fibroblast (Dixit et al., 1986b) libraries. TS is released from 
platelet alpha-granules upon activation and plays an essential 
role in the secretion-dependent  phase of platelet aggregation 
(Leung,  1984). In addition,  TS is secreted by a variety of 
cells in culture and may be a transient  component of the 
extracellular matrix (see review by Majack and Bornstein, 
1987). TS binds a variety of ligands including heparin (Law- 
ler and Slayter, 1981; Dixit et al.,  1984b), collagen (Lahav 
et al., 1982; Mumby et al., 1984), fibronectin (Lahav et al., 
1982), fibrinogen (Dixit et al., 1984a), plasminogen (Silver- 
stein et al., 1984, 1986), and plasminogen activator (Silver- 
stein et al., 1985, 1986). The formation of a ternary complex 
among TS, plasminogen,  and plasminogen activator may be 
of particular importance extravascularly for the facilitation 
1. Abbreviations used in this paper: PDGF, platelet-derived  growth factor; 
SMC,  smooth muscle cells; TS, thrombospondin. 
of plasmin generation in nonfibrin-containing environments 
such as the extracellular matrix (see review by Silverstein et 
al.,  1986). 
A variety of evidence suggests that TS may play an impor- 
tant role in the growth response of mesenchymal cells.  In 
vascular smooth muscle cell (SMC) cultures,  TS synthesis 
is regulated by platelet-derived growth factor (PDGF) (Ma- 
jack et al.,  1985). This regulation is effected at the mRNA 
level (Majack et al.,  1987). The rapid induction of the "IS 
message, together with its superinducibility in the combined 
presence of PDGF and cycloheximide, suggests that TS may 
be a member of the "competence" gene family that mediates 
the mitogenic response of cells to PDGF (Kelly et al., 1983; 
Cochran et al., 1983, 1984). Once secreted, TS binds to the 
SMC surface and extracellular matrix (Majack et al., 1985). 
TS plays a poorly understood role in the facilitation of the 
SMC response to epidermal growth factor (Majack et al., 
1986). Finally, heparin-like molecules, which are potent in- 
hibitors  of SMC  growth  (Clowes  and  Karnovsky,  1977; 
Castellot et al., 1981), inhibit the binding of TS to the SMC 
surface (Majack et al.,  1985) and prevent the TS/epidermal 
growth factor-mediated mitogenesis (Majack et al.,  1986). 
In this report we present antibody inhibition data support- 
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quired for the proliferation of vascular SMC. 
Materials and Methods 
Cell Culture 
Rat  aortic SMC  were  grown  from explants  from  the  vessels  of male 
Sprague-Dawley  rats as described previously  (Majack and Clowes,  1984). 
Cells were subcultured  in Waymouth's medium supplemented  with 5 % FBS 
and were used in the third through sixth passage, All culture materials were 
purchased  from Gibco (Grand Island, NY).  Cultures were photographed 






=  20  Antibodies  ! 
Polyclonal and monoctonal antibodies against purified  human platelet TS  ~  10 
were prepared and characterized as previously  described (Galvin et al.,  "~ 
1985; Dixit et al., 1985a, b, 1986a). Monoclonal antibody A2.5 recognizes  ~  0 
an epitope  on the heparin-binding domain of the TS molecule; A6.1 and 
A4.1  recognize  the  trypsin-resistant 70-kD  core;  C6.7 recognizes  the  50 
platelet-binding  domain; and D4.6 recognizes the 50-kD fragment contain- 
ing the fibrinogen-binding  domain. Antibodies A6.1 and D4.6 preferentially  40 
recognize TS prepared in the presence of EDTA and are thus conformation 
dependent. The monoclonal  antibodies used in the experiments  reported  30 
here were  isolated  on a  protein A-sepharose  affinity  column (Bio-Rad 
Laboratories,  Richmond, CA) and were stored as stock concentrations of 
1-2 gg/ml. Antibodies were filter sterilized before use, The polyclonal anti- 
body recognized all chymotryptic fragments of TS on Western blots. Anti-  112 
body  MIFI1, against the T antigen of SV-40, was a generous gift of Drs. 
L. R. Gooding and Ann Berger. Dr. John MacDonald kindly provided the 
monoclonal  antibodies (M-53 and N-294) against human fibronectin. 
Growth Assays 
All assays were performed in Waymouth's medium supplemented  with 5 % 
FBS with or without the indicated  concentration of antibody.  SMC were 
plated at densities of 5  x  103 cells/cm  2 in 16-mm-diam wells. Cells were 
counted electronically  with a coulter counter (model  ZM; Coulter Elec- 
tronics,  Luton, England) 24 h later (= day-O control) and at the indicated 
time points. Antibodies were added to fresh culture medium 24 h after plat- 
ing. Cultures were not refed for the duration of the experiment. All experi- 
ments were performed in triplicate wells and were done a minimum of three 
times.  The  percent inhibition of growth  was  derived by the  following 
formula: 
(  net  rowth of treated ceUs )  g  ____ 
% inhibition =  I  -  net growth of control cells  x  t00. 
Values for the net growth of cells were derived by subtracting the cell num- 
ber after plating (at day 0)  from the final experimental  cell number (at 
day 3). 
Flow Microfluorimetry 
Flow cytometric  analysis  was performed  on control cells on day 3 and on 
IM.6-treated cells on day 5 (see Results). Cells were harvested by mild tryp- 
sinization  and prepared for analysis as described by Adams et aL (1981). 
Samples  (1-2  x  106 cells) were gently pelleted  and resuspended  in 3 ml 
cold Puck's saline without Mg  +~ and glucose.  Cells were then fixed by 
three rapid additions of ice-cold absolute ethanol, with vigorous pipetting 
between additions.  Fixed  samples  were stored  at 4~  then were pelleted 
and resuspended  at 1-2  ￿  106 cells/ml in a 0.9%  NaCI,  15 mM MgCI2 
staining solution containing 50 I.tg mithramycin (Dome Laboratories,  West 
Haven, CT) per ml. Mithmmycin-stained  cells were analyzed for DNA~con  - 
tent using a FACS-II (Becton-Dickinson & Co., Sunnyvale, CA) and a nu- 
clear  data  acquisition  computer  (model  ND660;  Nuclear  Data,  Inc., 
Schaumberg,  IL). DNA histograms were analyzed mathematically for cell 
cycle phase distribution on an IBM 3031 computer using a program based 
on the multiple Gaussian model first proposed by Fried (1977). This method 
has been described in detail by Gray and Dean (1980) and was implemented 
here using the nonlinear estimation program NONLIN  (Metzler et al., 
1974). 
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Figure L  Inhibition of SMC 
growth  by  monoclonal  anti- 
bodies against TS.  Rat aortic 
SMC  were plated at 5  x  103 
cells/cm  2,  allowed  to  attach 
and spread for 24 h, then al- 
lowed  to  proliferate  in  5% 
FBS  in the absence or pres- 
ence of monoclonal antibodies 
(at 50  Ixg/ml) against human 
platelet  TS.  Cell  numbers 
were determined electronically 
at day  0  (24  h  after plating) 
and  at  day  3.  The  percent 
inhibition of growth was de- 
termined as described in Ma- 
terials  and  Methods.  The 
inhibito  D,  activity  of  D4.6 
(bottom)  was  abolished  by 
preabsorption of the antibody 
to  TS-Sepharose  (PA-D4.6). 
M1Fll, a control antibody di- 
rected against the T antigen of 
SV-40,  had  no  inhibitory 
effect.  Similarly, cells treated 
with  antibody  vehicle  alone 
(Buffer) or  with  monoclonal 
antibodies against fibronectin 
(see text) were not growth in- 
hibited. 
Immunofluorescence 
SMC were plated at sparse or confluent densities on glass coverslips and 
allowed to attach and spread for 24 h. Cultures were left untreated or were 
exposed to 100 pg/ml heparin or 50 pg/ml D4.6 for48 h. Cells were washed 
extensively in PBS, then were fixed for 10 min at 4~  in 2.5% formalde- 
hyde. Under these conditions,  cell membranes were left intact and only ex- 
tracellular staining was observed. After several  PBS washes,  nonspecific 
binding sites were blocked with serum homologous to the species of origin 
of the secondary  (labeled) antibody. Cells were exposed to a 1:10 dilution 
of primary antibody (polyclonal  rabbit anti-human TS or polyclonal  goat 
anti-rat fibronectin)  for 60 min at room temperature.  The fibronectin anti- 
serum was purchased from Calbiochem-Behring Corp. (La Jolla, CA) and 
immunoprecipitated  a single radiolabeled band from SMC culture medium. 
FITC-labeled secondary antibodies were used at 1:500 dilutions. Cells were 
photographed  on a Zeiss Photomicroscope  II using fluorescence  or phase- 
contrast imaging. 
SDS-PAGE 
SMC were plated at sparse density and allowed to attach and spread for 
24 h. Metabolic labeling was performed by culturing cells with 40-60 }xCi/ 
ml  [3~S]methionine (Amersham Corp.,  Arlington Heights,  IL)  in Way- 
mouth's medium lacking methionine  and supplemented with 0.1 mg/ml BSA 
and 100 gg/ml heparin or 50 Ixg/ml D4.6 as indicated. Metabolically labeled 
cell layers and culture medium were harvested into protease inhibitors as 
previously  described (Majack et al.,  1985). Radiolabeled  proteins  were 
precipitated  in  10%  trichloroacetic acid,  dissolved in Laemmli  sample 
buffer, neutralized as required with 0.5M NaOH, and resolved on 6% poly- 
acrylamide gels in the presence of 50 mM dithiothreitol.  Gels were fixed, 
dried, and exposed  to x-ray film. 
Results 
We have used a well-characterized panel of monoclonal anti- 
bodies against human platelet TS (Galvin et al., 1985; Dixit 
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and IM.6-treated SMC (b). SMC were plated at 5  x 
103 cells/cm  2, allowed to attach and spread for 24 h, 
then were grown for 6 d in 5 % FBS with or without 
50 gg/ml 134.6. Antibody-treated cells (b) showed a 
reduced cell  number  but  exhibited no evidence of 
cell detachment, cell rounding, or cytotoxicity. Bar, 
100 Bm. 
et al.,  1985a,  b,  1986a)  to assess  the role of TS in SMC 
growth. SMC were plated at a density of 5  x  103 cells/cm  2 
and allowed to proliferate for 3 d  (day 0 of the experiment 
is 24 h after plating) in medium supplemented with 5 % FBS. 
Preliminary assays established that, under these conditions, 
SMC exhibited a >10-fold increase in cell number without 
surpassing  monolayer density (i.e.,  the cultures were not 
multilayered). Monoclonal antibodies were tested initially at 
50 l~g/ml. Fig. 1 presents a compilation of  data from a series 
of experiments (n always >3) expressed as percent inhibition 
of  growth (see Materials and Methods). Five monoclonal an- 
tibodies (A2.5, A4.1, A6.1, C6.7, and D4.6) were tested for 
growth-inhibitory activity in 3-d assays; inhibitory activity 
ranged from 45 to almost 70%. The four antibodies shown 
in the Fig.  1 (top) inhibited growth but also, in separate as- 
says,  inhibited SMC adhesion and/or spreading on TS sub- 
strates  (Varani,  J.,  personal  communication).  Only  D4.6 
had no significant effect on cellular adhesion or spreading 
(see also Varani et al.,  1986; Roberts et at., 1987). We there- 
fore chose to study the growth-regulatory effects of D4.6 in 
greater detail. 
As presented in Fig. 1 (bottom) a number of controls con- 
vinced us that the effects  of these antibodies were TS specific. 
Preabsorption of D4.6 on a TS-sepharose affinity column re- 
moved the inhibitory activity. Similarly, addition of  an irrele- 
vant IgG antibody (M1Fll, against the Big T antigen of SV- 
40) or the vehicle buffer alone did not inhibit SMC growth. 
In  addition,  two  monoclonal  antibodies  against  plasma 
fibronectin (known to interact with fibronectin in extracellu- 
lar matrices) had little (N-294) or no (M-53) growth-inhibi- 
tory activity (not shown). SMC treated with 134.6 showed no 
morphological alterations and remained fully spread and at- 
tached (Fig. 2). While differences in cell density were obvi- 
ous,  no  noticeable  alterations  in  behavioral  organization 
(i.e., cell grouping or multilayering) were observed. 
The effects of D4.6 were concentration dependent over a 
range of 1-50 gg/ml (Fig. 3). Addition of 100 ttg/ml antibody 
resulted in a  slightly greater inhibitory effect. However, at 
Majack et al.  Thrornbospondin and SMC Growth  417 50 
4O 
i 




1  5  10  25  50 
antibody concentration (~9/ml) 
Figure 3.  Concentration-dependent  inhibition of SMC growth by 
D4.6.  Cell number assays were performed as described in the leg- 
end to Fig.  1 and the percent inhibition of growth was determined 
as described in Materials and Methods. SMC were treated with in- 
creasing amounts of D4.6 (1-50 Ixg/ml) and showed a dose-depen- 
dent inhibition of growth over the 3-d assay period. 
this concentration,  SMC showed some rounding and detach- 
ment. We therefore used a concentration of 50 ~tg/ml for sub- 
sequent  experiments. 
Fig. 4  illustrates the growth-inhibitory effects of 50 Ixg/ml 
D4.6 as a function of time. An inhibitory effect was observed 
at 1 d after addition of antibody and increased with time (to 
nearly 70%  inhibition  at day 8).  Note that all previous ex- 
periments were 3 d in duration when the inhibition is some- 
what less. 
Flow microfluorimetry was used to generate DNA histo- 
grams of control and D4.6-inhibited  cells, to determine the 
cell cycle compartment affected by D4.6.  Control cells were 










Figure 4. Time course of SMC 
growth  inhibition  by  I)4.6. 
SMC were plated at 5  x  103 
cells/cm  2,  allowed  to  attach 
and spread for 24 h, then were 
grown in 5 % FBS for 8 d  in 
the  absence  ([3) or presence 
(zx) of 50  lxg/ml  D4.6.  Cell 
numbers were determined  elec- 
tronically at the indicated time 
points.  1)4.6-treated  SMC 
showed  a  markedly  reduced 
growth rate and final cell den- 
sity and were essentially quies- 
cent by 6 d of treatment. 
at day 5. As shown in Fig. 4, under these conditions cell den- 
sities are identical,  control cells are in exponential growth, 
and  D4.6-treated  cells  are  nearly  quiescent.  D4.6-treated 
SMC  showed a  36%  decrease  in S  phase and  G2/M phase 
cells  and  a  concomitant  increase  in  G1  cells  (not  shown), 
suggesting that growth arrest occurs in the GI phase of the 
cell cycle. 
We  next  used  immunofluorescence  techniques  to  deter- 
mine the distribution  of "IS in SMC  cultures.  SMC  at sev- 
eral densities were examined after formaldehyde fixation and 
staining with a polyclonal antibody against TS. Because this 
fixation protocol  does  not  disrupt  the  integrity  of the  cell 
membrane, the staining observed reflects only extracellular 
(cell surface) TS. As shown in Fig.  5 a, immunostaining of 
SMC near monolayer confluency revealed a uniform distri- 
bution of TS over the cell surface. As previously reported for 
methanol-fixed,  permeabilized SMC (Majack et al.,  1985), 
the staining was dependent upon exposure of the cells to se- 
Figure 5.  Immunofluorescence localization of TS in SMC cultures.  The distribution of TS on SMC  surfaces was examined using im- 
munofluorescence techniques as described in Materials and Methods.  (a) Uniform distribution of TS on the SMC surface under control 
culture conditions. (b) Lack of immunostaining for "IS on SMC (at the same cell density as in a) treated with 100 Ixg/ml heparin for 48 h 
before fixation.  Cells maintained in 0.5 % FBS or stained with secondary antibody only also exhibited no cell surface staining.  Bars, 50 l~m. 
The Journal of Cell Biology, Volume 106,  1988  418 Figure 6. Immunofluorescence distribution of TS and fibronectin in control and D4.6-treated SMC. The distribution of'IS and fibronectin 
on the cell surfaces of SMC cultured in the absence or presence of D4.6 was examined using immunofluorescence techniques as described 
in Materials and Methods. (a) Paired phase-contrast and immunofluorescence photographs of  control SMC showing extensive surface stain- 
ing for TS. (b) Paired phase-contrast and immunofluorescence photographs of SMC treated for 48 h with 50 l.tg/ml D4.6, showing a marked 
reduction in the amount of  surface-associated TS. (c) Distribution of fibronectin on the surface of  control SMC. (d) Distribution of  fibronec- 
tin on the surface of D4.6-treated SMC. Note that D4.6 reduces the levels of stainable TS on the SMC surface without affecting the cell 
surface distribution  of fibronectin.  Bar, 50 vtm. 
rum or PDGF and could be markedly reduced by preaddition 
of heparin  to  the  culture  medium  (Fig.  5  b).  No  immu- 
nofluorescence was observed if the primary antibody was 
omitted from the staining protocol or if the primary antibody 
was preabsorbed to purified TS. 
Control and D4.6-arrested cells (day 5) were stained with 
a  polyclonal antibody against TS or with a polyclonal anti- 
body against fibronectin.  The TS antibody used recognizes 
all  chymotryptic  fragments  of  TS  on  Western  blots  and 
should,  therefore,  detect TS  immunologically even in  the 
presence of bound D4.6. As presented in Fig. 6, D4.6-treated 
SMC possessed significantly less stainable TS on their cell 
surfaces than did control cells. Thus D4.6 appears to mimic 
heparin in its ability to reduce cell surface TS (see Fig. 5 b). 
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rin on levels of TS in SMC culture 
supernatant. Sparsely plated, pro- 
liferative SMC were metabolically 
labeled for 2 h with [3sS]methio- 
nine in the absence (lane 1, con) or 
presence of 50 Ixg/ml  D4.6 (lane 2, 
D4.6) or 100 gtg/ml  heparin (lane 3, 
hep).  Radiolabeled proteins from 
the  culture  supernatant were re- 
solved by SDS-PAGE and visual- 
ized by autoradiography.  The posi- 
tions  of migration of fibronectin 
(FN) and thrombospondin  (TS) are 
indicated. Treatment of SMC with 
D4.6 or heparin increases relative 
levels of TS in the culture medium; 
both of these agents decrease the 
amount of  immunodetectable  TS on 
the SMC surface (see Fig. 5 and 6) 
and,  concomitantly, inhibit SMC 
proliferation. 
Duplicate wells were stained to visualize the distribution of 
fibronectin (Figure 6,  c and d).  There were no detectable 
differences in the relative amounts or distribution of cell sur- 
face fibronectin in control vs. D4.6-inhibited cells, suggest- 
ing that D4.6 does not inhibit proliferation through a general- 
ized  disruption  of the  extracellular  matrix.  Instead,  the 
inhibitory effect  appears to correlate with a reduced presence 
of TS on the SMC surface. 
An alternate possible explanation for the reduction in sur- 
face TS staining after D4.6 treatment is that D4.6 may bind 
to  surface-associated TS  in situ and sterically inhibit the 
binding of the polyclonal antibody used for immunostaining. 
We have addressed this issue by metabolically labeling SMC 
with [3SS]methionine for 2 h in the absence or presence of 
D4.6 or heparin. Our previous work (Majack et al.,  1985) 
documented the ability of heparin to block the incorporation 
of newly synthesized TS into the SMC matrix; a concurrent 
increase in the amount of labeled TS in the culture superna- 
tant was a characteristic of this effect.  As shown in Fig. 7, 
treatment of SMC with D4.6 or heparin resulted in increased 
levels of TS in the culture medium. Subsequent treatment of 
the D4.6-treated culture supernatant with protein A-Sepha- 
rose revealed that a  majority of the  secreted "IS was as- 
sociated with antibody. Cell layer-associated TS could not 
be visualized, in these experiments, by SDS-PAGE and auto- 
radiography. These labeling data, together with the immuno- 
staining data presented in Fig. 6, are fully consistent with the 
hypothesis that D4.6,  like heparin, prevents the interaction 
of newly synthesized TS with the SMC surface. 
Discussion 
Extracellular or cell surface proteins appear to play impor- 
tant roles in the control of cellular proliferation. Membrane- 
associated growth-inhibitory proteins may function in den- 
sity-dependent growth arrest (Lieberman and Glaser, 1981). 
Proteases secreted in response to growth factors (e.g., Gal 
and Gottesman, 1986) may play important roles in degrada- 
tion of the extracellular matrix, a process believed essential 
for cell proliferation. Other cell surface molecules, such as 
the receptorlike protooncogenesfms and neu (Manger et al., 
1984; Drebin et al.,  1985; Sherr et al.,  1985; Stern et al., 
1986) or the 83-kD protein described by Wetland et al. (1986), 
may play unknown but growth-facilitative  roles. Components 
of the extracellular matrix, which may influence cell shape, 
adhesion, or spreading, also appear to exert growth-regula- 
tory functions (Gospodarowicz and I11, 1980). In this report 
we provide further evidence that TS, a PDGF-regulated cell 
surface protein, may play an important functional role in the 
proliferation of vascular SMC. 
We have shown that a  panel of monoclonal antibodies, 
which recognize distinct epitopes along the TS molecule, can 
inhibit the proliferation of SMC in culture. These data are 
an extension of earlier studies that indirectly suggested some 
growth-regulatory function for TS.  Other data that imply 
such a role for TS include (a) the rapid induction of the "IS 
mRNA and protein after stimulation of SMC with PDGF 
(Majack et al., 1985, 1987), (b) similarities in the effects of 
metabolic inhibitors on mRNA levels for TS (Majack et al., 
1987) and other PDGF-induced growth-regulatory proteins 
such as c-myc (Kelly et al., 1983) and c-fos (Cochran et al., 
1984),  (c)  the  enhanced  response  of SMC  to  epidermal 
growth factor after exposure of the cells to purified TS (Ma- 
jack et al., 1986), and (d) the apparent correlation between 
the inhibition of SMC growth by heparin (Clowes and Kar- 
novsky, 1977; Castellot et al., 1981) and the ability of heparin 
to block the binding of TS to cell membranes (McKeown- 
Longo et al.,  1984; Majack et al.,  1985; Roberts  et al., 
1985). In this report we show that D4.6 reduces the associa- 
tion of TS with the SMC surface and concomitantly inhibits 
cellular proliferation. We propose that cell surface-associ- 
ated TS is functionally essential for the proliferation of vas- 
cular SMC. 
Monoclonal antibodies to five different epitopes along the 
TS molecule were roughly equivalent in their abilities to in- 
hibit SMC growth (Fig. 1). This surprising observation does 
not allow us to conclude which domain(s) of  the TS molecule 
is important for SMC growth. The observed data may result 
from the ability of'IS to interact with cell surfaces via multi- 
ple sites,  as hypothesized by Roberts et al. (1987). In their 
studies, antibodies A2.5, A6.1, and C6.7 all inhibited mela- 
noma cell attachment and spreading. Similar data have been 
reported by Varani  et al.  (1986) for squamous carcinoma 
cells. The interaction of fibronectin with cell surfaces may 
also occur via multiple sites (Akiyama et al.,  1985). Alter- 
nately, the data may reflect an ability of the antibodies to in- 
duce conformational changes in TS that affect the functional 
characteristics of  the molecule, as shown previously for anti- 
body A2.5 (Galvin et al.,  1985). Little is known about the 
conformational state of TS in vivo. Our data suggest that the 
conformation of TS in cell culture conditions may be similar 
to that induced by EDTA, since the conformation-dependent 
antibodies A6.1 and D4.6 (Dixit et al. 1986a) are effective in 
preventing SMC proliferation. This contention is supported 
by the attachment data cited above (in which A6.1 was shown 
to be an effective  inhibitor of cell attachment) and by im- 
munolocation studies using D4.6 as a primary antibody (per- 
sonal observations). 
What is the function of cell-associated TS and how might 
this function be involved in cell growth control? Silverstein 
and co-workers (1984, 1985, 1986) have shown that TS inter- 
The Journal  of Cell Biology, Volume 106,  1988  420 acts with plasminogen and plasminogen activator  in a ter- 
nary  complex  that  facilitates the  formation  of plasmin  in 
nonfibrin-containing environments.  Furthermore,  the plas- 
min generated  remains bound to TS and is protected from in- 
activation  by plasmin inhibitors (Silverstein et al., 1986).  TS 
may therefore play an important role in the extracellular ma- 
trix via  its  ability  to facilitate  the matrix degradation  and 
remodeling  that  accompanies  the  proliferation  of mesen- 
chymal cells. This concept is consistent with other reports 
that have described a very short  (<90 min) half-life of ex- 
tracellular  TS (McKeown-Longo et al., 1984),  and with our 
unpublished data that suggest that surface-bound TS may be 
capped, presumably after use, and accumulated at the trail- 
ing  edge  of the  cells.  Further  experimentation  is  clearly 
needed to clarify the functional role and metabolic fate of TS 
on the cell surface. 
Finally,  we feel that the data presented in this paper pro- 
vide  further  evidence  that heparin-like molecules may  in- 
hibit SMC growth through  a mechanism involving TS (Ma- 
jack et al., 1985, 1986).  The molecular mechanism by which 
heparin inhibits SMC growth (Clowes and Karnovsky,  1977; 
Castellot et al.,  1981) and migration (Majack  and Clowes, 
1984) is not known but is likely to be external given the small 
amount of input heparin internalized during binding assays 
(Castellot et al.,  1985).  After growth stimulation,  SMC in 
culture produce a TS-rich extracellular matrix (Majack  et 
al.,  1985).  In the presence of heparin, the incorporation of 
TS into the SMC surface and matrix is markedly inhibited 
(Majack et al., 1985).  We now show that D4.6, like heparin, 
blocks the interaction  of TS with SMC and, concomitantly, 
cell proliferation.  The data  suggest  important  growth-reg- 
ulatory  functions  for TS  interactively  associated  with cell 
surfaces. 
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